ClinicalTrials.gg
CompletedNCT03833180Updated Jan 12, 2024

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

A Phase 1 interventional study of Zilovertamab vedotin in Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma and Follicular Lymphoma, sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
91
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Merck & Co., Inc — 3 open to participants now, 6 under way, 3 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Merck & Co., Inc.

Enrollment
6th of 11
91 · median 91
Started
2019
the only one that year
Phase 1
3 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Merck & Co., Inc, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 3 in phase 1, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 11 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Merck & Co., Inc, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Richter transformation lymphoma (RTL), and T-cell non-Hodgkin lymphoma (NHL).

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Richter Transformation Lymphoma
  • Burkitt Lymphoma
  • Lymphoplasmacytoid Lymphoma
  • T-cell Non-Hodgkin Lymphoma
  • Acute Lymphoid Leukemia
  • Acute Myeloid Leukemia
  • Waldenstrom Macroglobulinemia

Keywords

  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Leukemia, B-Cell
  • Leukemia, Lymphoid
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Follicular
  • Lymphoma, Mantle-Cell
  • Burkitt Lymphoma
  • Lymphoma, Lymphoplasmacytoid
  • Waldenström Macroglobulinemia
  • Lymphoma, T-cell
  • Leukemia, Lymphoid, Acute
  • Leukemia, Myeloid, Acute
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women of age ≥18 years.
  • (ECOG) performance status of 0, 1, or 2.
  • Histological diagnosis of CLL/SLL, MCL, FL, MZL, DLBCL, RTL, BL, LPL/WM, T-cell NHL, ALL, or AML as documented in medical records.
  • Hematological cancer under study has been previously treated and has progressed during or after prior systemic therapy.
  • Hematological cancer is unlikely to be responsive to established therapies known to provide clinical benefit or the study candidate has developed an intolerance to established therapies known to provide clinical benefit.
  • Presence of measurable cancer including CLL/SLL, MCL, FL, MZL, DLBCL, RTL, BL, LPL/WM, T-cell NHL, ALL, and AML.
  • Current medical need for therapy due to disease-related symptoms or complications, cytopenias, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease.
  • Availability of pretreatment tumor tissue.
  • Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or therapy) for the treatment of cancer ≥1 week before the start of study therapy.
  • All acute toxic effects of any prior antitumor therapy (not including hydroxyurea, cytarabine, and/or cyclophosphamide used in subjects with acute leukemia) resolved to ≤Grade 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted] or selected laboratory parameters [Grade 1 or Grade 2 permitted with exceptions.
  • Adequate bone marrow function.
  • Adequate hepatic profile.
  • Adequate renal function.
  • Adequate coagulation profile.
  • Negative antiviral serology.
  • For female participants of , a negative serum pregnancy test.
  • For both male and female participants, willingness to use protocol-recommended method of from the start of the screening period until ≥6 months after the final dose of study therapy.
  • Willingness and ability of the participant to comply with study activities.
  • Evidence of a personally signed document.
  • Previous treatment with an MMAE-containing drug is allowed.

Exclusion criteria

Exclusion Criteria:

  • Presence of involving the central nervous system.
  • Presence of another cancer with disease manifestations or therapy that could adversely affect participant safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
  • Significant cardiovascular disease within 3 months prior to start of study therapy.
  • Significant screening (ECG) abnormalities.
  • Uncontrolled ongoing systemic bacterial, fungal, or viral infection.
  • Known diagnosis of liver cirrhosis.
  • Pregnancy or breastfeeding.
  • Candidacy for hematopoietic stem cell transplantation () or chimeric antigen receptor (CAR)-T-cell therapy with access to HSCT or CAR-T cells and a willingness to undergo such therapy.
  • In participants with prior HSCT, evidence of (GVHD) with Grade ≥2 serum , Grade ≥3 skin involvement, or Grade ≥3 diarrhea.
  • Prior solid organ transplantation.
  • Major surgery within 4 weeks before the start of study therapy.
  • Prior therapy with a receptor tyrosine kinase-like orphan receptor 1 (ROR1)-directed therapy.
  • Has ongoing therapy (exceeding 30 mg daily of prednisone equivalent). Prednisone equivalent dosing must have been stable for at least 4 weeks prior to Cycle 1 Day 1 (C1D1). If corticosteroid treatment is required for lymphoma symptom control prior to C1D1, up to 100 mg per day of prednisone equivalent can be given for up to 5 days. In that case, all tumor assessments must have been completed prior to the start of corticosteroid treatment.
  • Use of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4.
  • Use within 7 days prior to the start of study therapy of a drug known to prolong the .
  • Concurrent participation in another therapeutic or imaging clinical trial.
  • Presence of a medical condition that (in the judgement of the investigator) interferes with the ability of the participant to participate in the study.
  • Has baseline peripheral neuropathy >Grade 1.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Zilovertamab vedotin Schedule 1: Q1/3W

    Participants will be administered escalating doses of zilovertamab vedotin at 0.50, 1.00, 1.50, 2.25, 2.50, 2.75, and 3.00 mg/kg IV on Day 1 of repeated 21-day cycles (Q1/3W).

    Drug: Zilovertamab vedotin

  • Experimental
    Zilovertamab vedotin Schedule 2: Q2/3W

    Participants will be administered escalating doses of zilovertamab vedotin at 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, and 2.25 mg/kg IV on Day 1 and 8 of repeated 21-day cycles (Q2/3W).

    Drug: Zilovertamab vedotin

  • Experimental
    Zilovertamab vedotin Schedule 3: Q3/4W

    Participants will be administered escalating doses of zilovertamab vedotin at 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, and 2.25 mg/kg IV on Day 1, 8, and 15 of repeated 21-day cycles (Q3/4W).

    Drug: Zilovertamab vedotin

Interventions

  • Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.

    Also known as: VLS-101, MK-2140

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of zilovertamab vedotin

    Participants will receive zilovertamab vedotin according to Schedule 1, 2, or 3. The MTD will be determined by the number of participants who experience a dose limiting toxicity (DLT). The MTD will be defined as the highest tested dose level at which ≥6 participants have been treated and which is associated with a Cycle 1 DLT in ≤17% of the participants.

    Time frame: Cycle 1 (Up to 21 Days)

  2. Recommended Dosing Regimen (RDR)

    Selection of the RDR will be based on consideration of short- and long-term safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The RDR may be the MTD or may be a lower dose within the tolerable dose range.

    Time frame: Cycle 1 (Up to 21 Days)

Secondary outcomes

  1. Average number of zilovertamab vedotin infusions administered

    Zilovertamab vedotin drug administration will be assessed by prescribing records and the average number of zilovertamab vedotin infusions administered will be determined.

    Time frame: Up to 5 months

  2. Number of participants with a treatment-emergent adverse event (TEAE)

    An AE is any untoward medical occurrence in a participant administered a medicinal product; the event does not necessarily have a causal relationship with study drug administration or usage. Laboratory abnormalities, vital sign/oxygen saturation abnormalities, and adverse electrocardiogram (ECG) findings will also be recorded as AEs. A TEAE is defined as an AE that occurs or worsens in the period from the first dose of study drug administration to 30 days after the final dose of study drug administration. The number of participants with a TEAE will be reported for each arm.

    Time frame: Up to approximately 3.5 years

  3. Number of participants with a DLT

    A DLT is defined as a protocol pre-specified TEAE that occurs in Cycle 1 of zilovertamab vedotin therapy and is considered drug-related. Failure to recover to baseline by ≥21 days from the last dose of study drug in the current cycle due to a drug-related TEAE is also considered a DLT. The number of participants with a DLT will be reported for each arm.

    Time frame: Cycle 1 (Up to 21 Days)

  4. Number of participants with a serious adverse event (SAE)

    An SAE is defined as an untoward medical occurrence that results in any of the following outcomes: death, life-threatening situation, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or other medically significant event.

    Time frame: Up to approximately 3.5 years

  5. Number of participants with an adverse event of special interest (AESI)

    Prespecified AESIs for this study will include: Grade ≥3 infusion reactions, tumor lysis syndrome (TLS) of any grade, and Grade ≥3 peripheral neuropathy. The number of participants with an AESI will be reported for each arm.

    Time frame: Up to approximately 3.5 years

  6. Number of participants that discontinue study treatment due to an AE

    An AE is any untoward medical occurrence in a participant administered a medicinal product; the event does not necessarily have a causal relationship with study drug administration or usage. The number of participants that discontinue study treatment due to an AE will be reported for each arm.

    Time frame: Up to approximately 3.5 years

  7. Number of participants that use supportive care or concomitant medications

    The number of participants that use supportive care or concomitant medications will be reported for each arm.

    Time frame: Up to approximately 3.5 years

  8. Plasma concentration of zilovertamab vedotin

    Plasma concentration of zilovertamab vedotin will be reported for each arm.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  9. Plasma concentration of total UC-961 antibody

    Plasma concentration of total UC-961 antibody will be reported for each arm.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  10. Plasma concentration of monomethyl auristatin E (MMAE)

    Plasma concentration of MMAE will be reported for each arm.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  11. Maximum plasma concentration (Cmax) of zilovertamab vedotin

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Cmax of zilovertamab vedotin.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  12. Time to maximum plasma concentration (Tmax) of zilovertamab vedotin

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Tmax of zilovertamab vedotin.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  13. Area under the plasma concentration time curve (AUC) of zilovertamab vedotin

    Blood samples collected predose and at multiple timepoints postdose will be used to determine AUC of zilovertamab vedotin.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  14. Volume of distribution (Vd) of zilovertamab vedotin

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Vd of zilovertamab vedotin.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  15. Clearance (CL) of zilovertamab vedotin

    Blood samples collected predose and at multiple timepoints postdose will be used to determine CL of zilovertamab vedotin.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  16. Apparent terminal half-life (t½) of plasma concentration of zilovertamab vedotin

    Blood samples collected predose and at multiple timepoints postdose will be used to determine t1/2 of plasma concentration of zilovertamab vedotin.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  17. Cmax of total UC-961 antibody

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Cmax of total UC-961 antibody.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  18. Tmax of total UC-961 antibody

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Tmax of total UC-961 antibody.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  19. AUC of total UC-961 antibody

    Blood samples collected predose and at multiple timepoints postdose will be used to determine AUC of total UC-961 antibody.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  20. Vd of total UC-961 antibody

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Vd of total UC-961 antibody.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  21. CL of total UC-961 antibody

    Blood samples collected predose and at multiple timepoints postdose will be used to determine CL of total UC-961 antibody.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  22. t1/2 of plasma concentration of total UC-961 antibody

    Blood samples collected predose and at multiple timepoints postdose will be used to determine t1/2 of plasma concentration of total UC-961 antibody.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  23. Cmax of MMAE

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Cmax of MMAE.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  24. Tmax of MMAE

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Tmax of MMAE.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  25. AUC of MMAE

    Blood samples collected predose and at multiple timepoints postdose will be used to determine AUC of MMAE.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  26. Vd of MMAE

    Blood samples collected predose and at multiple timepoints postdose will be used to determine Vd of MMAE.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  27. CL of MMAE

    Blood samples collected predose and at multiple timepoints postdose will be used to determine CL of MMAE.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  28. t1/2 of plasma concentration of MMAE

    Blood samples collected predose and at multiple timepoints postdose will be used to determine t1/2 of plasma concentration of MMAE.

    Time frame: Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion

  29. Number of participants with zilovertamab vedotin-reactive antibodies

    Number of participants with zilovertamab vedotin-reactive antibodies will be assessed.

    Time frame: Day 1 of Cycles 1 through end of therapy (up to approximately 3.5 years): predose and end of infusion (up to ~30 minutes)

  30. Overall Response (OR)

    OR will be defined by achievement of the following outcomes as indicated by disease type: CLL/SLL: Complete response (CR: disappearance of detectable disease per Cheson 2012 criteria), CR with incomplete blood count recovery (CRi: CR with ≥1 additional change in absolute neutrophil count, platelet count, or hemoglobin), partial response (PR: no evidence of new disease per Cheson 2012 criteria), or PR with lymphocytosis (PR except lack of decrease in peripheral blood absolute lymphocyte count); NHL: CR (disappearance of all detectable disease per Cheson 2014 criteria) or PR (≥50% decrease in the sum of the product of diameters of the index nodal and extranodal lesions); LPL/WM: CR, very good PR (CR with ≥90% decrease in M protein), PR, or minor response (criteria for PR or stable disease met per Cheson 2014); ALL: (CR, CRi, unconfirmed CR, or PR per National Comprehensive Cancer Network criteria); AML (CR, CRi, morphologic leukemia-free state \[MLFS\], or PR per Cheson 2003 criteria).

    Time frame: Up to approximately 3.5 years

  31. Complete Response without measurable residual disease (CRMRD-)

    CRMRD- is defined as the achievement of ≤1 × 10\^-4 malignant cells in bone marrow (as assessed by flow cytometry) in a participant who meets all other criteria for CR.

    Time frame: Up to approximately 3.5 years

  32. Percent change from baseline in tumor dimension

    Percent change in tumor dimensions is defined as the percent change from baseline in the sum of the products of the diameters (SPD) of index lesions.

    Time frame: Up to approximately 3.5 years

  33. Time to Response (TTR)

    TTR is defined as the interval from the start of study therapy to the first documentation of an objective response.

    Time frame: Up to approximately 3.5 years

  34. Duration of Response (DOR)

    DOR is defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression/relapse or death from any cause.

    Time frame: Up to approximately 3.5 years

  35. Progression free survival (PFS)

    PFS is defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression/relapse or death from any cause.

    Time frame: Up to approximately 3.5 years

  36. Time to Treatment Failure (TTF)

    TTF failure is defined as the interval from start of study therapy to the earliest of the first documentation of disease progression/relapse, treatment failure (for participants with ALL or AML), the permanent cessation of study drug due to an AE, or death from any cause.

    Time frame: Up to approximately 3.5 years

  37. Overall Survival (OS)

    OS is defined as the interval from the start of study therapy to death from any cause.

    Time frame: Up to approximately 3.5 years

07

Study locations

14 sites
  • City of Hope ( Site 0010)
    Duarte, California 91010, United States
  • University of California - San Diego ( Site 0003)
    La Jolla, California 92093, United States
  • UCLA Hematology & Oncology ( Site 0007)
    Los Angeles, California 90095, United States
  • University of Nebraska Medical Center ( Site 0006)
    Omaha, Nebraska 68198-5331, United States
  • Northwell Health ( Site 0009)
    New Hyde Park, New York 11042, United States
  • Weill Cornell Medical College ( Site 0005)
    New York, New York 10021, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0014)
    New York, New York 10065, United States
  • University of Rochester ( Site 0008)
    Rochester, New York 14642, United States
  • Memorial Sloan-Kettering Cancer Center ( Site 0019)
    Uniondale, New York 11553, United States
  • Oregon Health & Science University ( Site 0004)
    Portland, Oregon 97239, United States
  • MD Anderson Cancer Center ( Site 0001)
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center ( Site 0011)
    Houston, Texas 77030, United States
  • University of Virginia Cancer Center ( Site 0012)
    Charlottesville, Virginia 22908, United States
  • Swedish Medical Center ( Site 0002)
    Seattle, Washington 98104, United States
08

References and documents

Publications

  • Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K, Kipps TJ, Rule S, Flanders K, Jessen KA, Ren H, Riebling PC, Graham P, King L, Thurston AW, Sun M, Schmidt EM, Lannutti BJ, Johnson DM, Miller LL, Spurgeon SE. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evid. 2022 Jan;1(1):EVIDoa2100001. doi: 10.1056/EVIDoa2100001. Epub 2021 Oct 12. PubMed 38319241 ↗
  • Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536. PubMed 34398557 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Dec 2023, 57 months.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 57 months is close to that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2019
First posted
Feb 6, 2019
StartActual
Mar 14, 2019
Primary completionActual
Dec 18, 2023
CompletionActual
Dec 18, 2023
Last update
Jan 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03833180
Responsible party
Sponsor
First posted
Feb 6, 2019
Start date
Mar 14, 2019
Primary completion
Dec 18, 2023
Completion
Dec 18, 2023
Last update
Jan 12, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilovertamab vedotin

Start the discussion